GLP-1 therapies represent a breakthrough in treating obesity as the chronic disease it truly is, offering hope to over 1 billion people worldwide. These medications reduce cardiovascular events, improve kidney disease and sleep apnea, and provide the first truly effective treatment option after six decades of inadequate solutions. Comprehensive care combining these therapies with behavioral support can transform lives and bend the curve on diabetes and related conditions.